Vascular Effects of Alirocumab in Acute MI-Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

April 25, 2017

Primary Completion Date

October 13, 2021

Study Completion Date

October 13, 2021

Conditions
Coronary VesselCoronary CirculationAtheroma; Myocardial
Interventions
DRUG

Alirocumab

Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50

Trial Locations (9)

1090

University Hospital Vienna (AKH), Vienna

1211

Hopitaux Universitaires Geneve, Geneva

2100

Rigshospitalet, Copenhagen

3010

Bern University Hospital Inselspital, Bern

3015

Erasmus Thoraxcentre, Rotterdam

4031

Basel University Hospital, Basel

6525

Radboud Univerity, Nijmegen Medical Centre, Nijmegen

8063

Stadtspital Triemli, Zurich

8091

University Hospital Zurich USZ, Zurich

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT03067844 - Vascular Effects of Alirocumab in Acute MI-Patients | Biotech Hunter | Biotech Hunter